Early research suggests Merck cancer drug may target dormant HIV
Antiretroviral treatments now allow many HIV patients to lead normal lives, but the drugs do not completely remove the virus from the body
January 29, 2022
by ExpressPharma
NICE approves lung cancer combination drug therapy for NHS use
People treated with pembrolizumab lived for 17.1 months on average versus 11.6 months for chemotherapy, trial data showed.
January 14, 2022
by Pharmaceutical-Technology
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that...
October 13, 2021
by prnasia
FDA Approves Breast Cancer Treatment
The FDA approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
July 29, 2021
by americanpharmaceuticalreview
FDA Approves Carcinoma Treatment
The FDA approved pembrolizumab (Keytruda - Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) ...
July 23, 2021
by americanpharmaceuticalreview
First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma
QBiotics Group Limited, a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology ...
June 3, 2021
by prnasia
Virus therapy shows promise against inoperable skin cancers
The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, coxsackievirus, to infect and kill cancer cells.
April 12, 2021
by expresspharma
USFDA sends CRL to Merck’s sBLA regarding KEYTRUDA
Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval of KEYTRUDA.
April 2, 2021
by pharmaceutical-business-review
FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma
The U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or ...
March 26, 2021
by americanpharmaceuticalreview
Linnaeus Granted Orphan Drug Designation for LNS8801 for Metastatic Uveal Melanoma
Linnaeus Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic uveal melanoma (MUM).
March 18, 2021
by americanpharmaceuticalreview
First person enrolled in Phase I oncolytic virus trial
The Phase I/IIa trial of BT-001 will assess the safety and efficacy of the virus’ dual mode of action in solid tumours.
March 4, 2021
by europeanpharmaceuticalreview
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
October 26, 2020
by europeanpharmaceuticalreview